Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1963 1
1964 2
1965 1
1966 3
1967 3
1968 4
1970 4
1971 7
1972 2
1973 2
1974 3
1975 2
1976 2
1977 10
1978 10
1979 7
1980 11
1981 15
1982 18
1983 23
1984 29
1985 23
1986 29
1987 44
1988 50
1989 47
1990 43
1991 52
1992 56
1993 75
1994 69
1995 75
1996 96
1997 126
1998 147
1999 225
2000 275
2001 281
2002 335
2003 357
2004 439
2005 482
2006 563
2007 648
2008 713
2009 828
2010 986
2011 1254
2012 1365
2013 1412
2014 1490
2015 1612
2016 1503
2017 1593
2018 1605
2019 1676
2020 1909
2021 2008
2022 1767
2023 1722
2024 605

Text availability

Article attribute

Article type

Publication date

Search Results

25,599 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Shitara K, et al. Among authors: park yk. Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19. Lancet Oncol. 2024. PMID: 38134948 Clinical Trial.
Engrailed-1 Promotes Pancreatic Cancer Metastasis.
Xu J, Roe JS, Lee E, Tonelli C, Ji KY, Younis OW, Somervile TDD, Yao M, Milazzo JP, Tiriac H, Kolarzyk AM, Lee E, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Borowsky AD, Park Y, Vakoc CR, Tuveson DA, Hwang CI. Xu J, et al. Among authors: park y. Adv Sci (Weinh). 2024 Feb;11(6):e2308537. doi: 10.1002/advs.202308537. Epub 2023 Dec 18. Adv Sci (Weinh). 2024. PMID: 38110836 Free PMC article.
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernandez-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Dunbar AJ, et al. Among authors: park yc. Cancer Discov. 2024 Jan 12. doi: 10.1158/2159-8290.CD-22-0952. Online ahead of print. Cancer Discov. 2024. PMID: 38230747 Free article.
Carbon-based nanocomposites for biomedical applications.
Shin M, Lim J, Park Y, Lee JY, Yoon J, Choi JW. Shin M, et al. Among authors: park y. RSC Adv. 2024 Feb 28;14(10):7142-7156. doi: 10.1039/d3ra08946k. eCollection 2024 Feb 21. RSC Adv. 2024. PMID: 38419681 Free PMC article. Review.
AIBP: A New Safeguard against Glaucomatous Neuroinflammation.
Choi S, Choi SH, Bastola T, Park Y, Oh J, Kim KY, Hwang S, Miller YI, Ju WK. Choi S, et al. Among authors: park y. Cells. 2024 Jan 21;13(2):198. doi: 10.3390/cells13020198. Cells. 2024. PMID: 38275823 Free PMC article. Review.
Targeting the dermis for melasma maintenance treatment.
Han HJ, Kim JC, Park YJ, Kang HY. Han HJ, et al. Among authors: park yj. Sci Rep. 2024 Jan 10;14(1):949. doi: 10.1038/s41598-023-51133-w. Sci Rep. 2024. PMID: 38200171 Free PMC article.
Unraveling the role of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer by multi-omics analyses.
Lee SE, Park S, Yi S, Choi NR, Lim MA, Chang JW, Won HR, Kim JR, Ko HM, Chung EJ, Park YJ, Cho SW, Yu HW, Choi JY, Yeo MK, Yi B, Yi K, Lim J, Koh JY, Lee MJ, Heo JY, Yoon SJ, Kwon SW, Park JL, Chu IS, Kim JM, Kim SY, Shan Y, Liu L, Hong SA, Choi DW, Park JO, Ju YS, Shong M, Kim SK, Koo BS, Kang YE. Lee SE, et al. Among authors: park yj. Nat Commun. 2024 Feb 8;15(1):1163. doi: 10.1038/s41467-024-45366-0. Nat Commun. 2024. PMID: 38331894 Free PMC article.
Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
Kim J, Kim TJ, Chae S, Ha H, Park Y, Park S, Yoon CJ, Lim SA, Lee H, Kim J, Kim J, Im K, Lee K, Kim J, Kim D, Lee E, Shin MH, Park SI, Rhee I, Jung K, Lee J, Lee KH, Hwang D, Lee KM. Kim J, et al. Among authors: park y. Mol Cancer. 2024 Feb 29;23(1):45. doi: 10.1186/s12943-024-01936-w. Mol Cancer. 2024. PMID: 38424542 Free PMC article.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Pusztai L, et al. Among authors: park yh. Ann Oncol. 2024 Feb 17:S0923-7534(24)00046-2. doi: 10.1016/j.annonc.2024.02.002. Online ahead of print. Ann Oncol. 2024. PMID: 38369015
25,599 results
You have reached the last available page of results. Please see the User Guide for more information.